

Neu-Ulm / Gauting, 01 November 2019

NUVISAN continues steady growth by acquiring Inamed GmbH

On November 1st, the NUVISAN group announced the acquisition of Inamed GmbH. Inamed is an international CRO, specialized in clinical trials with patients that suffer respiratory and rare diseases. This includes access to patient populations that are very difficult to recruit, such as patients with Cystic Fibrosis. Furthermore Inamed is one of very few CROs offering orally inhaled products flow profile studies with a combination of all associated skills (technical preparation of devices, flow-profile measurements, in house clinical performance, and management of some external pediatric sites) at the same CRO. Over the last several years NUVISAN and Inamed built up a close partnership through collaboration on a number of services. The current merger is the logical consequence of their long lasting successful cooperation.

„In NUVISAN we found the perfect and reliable partner to develop the business into the next growth phase. We are glad to become a family member of the NUVISAN group. Now we can fully participate in NUVISAN’s 40 years of experience, expertise, and international network“, summarizes Kerstin Lang, Managing Director of Inamed.

The site with a headcount of 28 specialists is located in the periphery of Munich and comes with an in-house clinical pharmacology unit of 24 beds plus 6 intensive monitoring beds. The short distance to NUVISAN headquarters ensures steady personnel exchange and just in time logistics between the sites.

"With the Inamed capabilities – to include the special field of respiratory studies and combined multi-center studies – we will extend our services in clinical trials with patients and increase our overnight facilities to 160 beds at the two sites. The Inamed acquisition is the next step of our continuous growth strategy to become an „All Pharma Services“ company in the field of early stage drug development for the pharmaceutical industry“, says Dr. Ralf Wulkow, Executive Vice President Clinical Services.

With Inamed services NUVISAN now completes its ability to offer a wider range of clinical trials, especially with aerosol biophysics and technology, drug discovery, and life science research with desired synergistic effects for all NUVISAN business units to become an even more complete CRO/ CDMO.

About NUVISAN GmbH

The NUVISAN group generates sales of approx. € 50 million and an EBITDA margin of > 15% with currently about 400 highly qualified employees. It originated from LAB GmbH over 40 years ago and has been operating under the name NUVISAN with its headquarters in Neu-Ulm since 2010. The NUVISAN group as a Clinical Research Organization (CRO) and Contract Manufacturing Organization (CDMO) has six sites (Neu-Ulm, Berlin, Grafing, Gauting, Waltrop/ Germany and Sophia-Antipolis/ France) in addition to monitoring activities with offices in Argentina, Peru and Brazil as well as in the USA.

Press Contact

Elmar Rothenfusser

Tel.: +49 731 9840 143

Email: elmar.rothenfusser@nuvisan.com

NUVISAN GmbH

Wegenerstr. 13

D-89321 Neu-Ulm